Chinese expert consensus on integrated management of cancer-related hypertension(2024 version)
10.12354/j.issn.1000-8179.2024.20241244
- VernacularTitle:肿瘤相关高血压整合管理中国专家共识(2024年版)
- Author:
Society of Integrative Cardio-Oncology,China Anti-Cancer Association
;
Expert Panel on Chinese Expert Consensus on Integrated Man-agement of Cancer-Related Hypertension
;
Li YUE
;
Zhang ZHIREN
- Keywords:
hypertension;
cancer;
cardio-oncology
- From:
Chinese Journal of Clinical Oncology
2024;51(19):993-1002
- CountryChina
- Language:Chinese
-
Abstract:
Cancer-related hypertension(CR-HTN)is a common and significant clinical issue in cancer patients,leading to poor prognosis.However,there is still a lack of unified understanding and standardized management for this condition.The Society of Integrative Cardio-On-cology,China Anti-Cancer Association,has developed this consensus based on clinical research evidence and practical experience.It provides a detailed overview of the epidemiology,pathogenesis,diagnosis and differential diagnosis,treatment,prognosis,and follow-up of CR-HTN.The consensus advocates for a proactive blood pressure monitoring strategy to detect CR-HTN early and recommends an integrated ap-proach combining anti-hypertensive and anti-cancer therapies to standardize the management of CR-HTN,thereby improving the diagnosis and treatment levels of CR-HTN in China.
